With no cost to join or shop, we help our independent pharmacy customers regain control of their business by providing price comparison shopping on their pharmaceutical purchases on a simple-to-use online system.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

COVID-19 BRINGS DIVISIONS ON HYDROXYCHLOROQUINE, REOPENING

Fiercepharma | May 19, 2020

news image

Welcome to the FiercePharma political roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewhere that could affect drug pricing and how drugmakers operate. As the pandemic plays out, political divisions have unfolded around hydroxychloroquine and reopening economies, for starters. At center stage last week was a House hearing over ousted Biomedical Advanced Research and Development Authority (BARDA) Director Rick Bright’s whistleblower complaint. While...

Read More

Business Insights

SANOFI GLOBAL HEALTH LAUNCHES NONPROFIT IMPACT® BRAND FOR 30 MEDICINES IN LOW-INCOME COUNTRIES

Sanofi | July 05, 2022

news image

Sanofi Global Health announces the launch of Impact®, a new brand of standard of care medicines produced by Sanofi dedicated for nonprofit distribution to at-risk populations in the world’s most impoverished countries. The Impact® brand, which includes insulin, glibenclamide and oxaliplatin amonst others, will enable the secure distribution of 30 Sanofi medicines in 40 lower-income countries. Considered essential by the World Health Organization, the medicines cover ...

Read More

Research, PHARMA TECH

ASKBIO RECEIVES EC ORPHAN DRUG DESIGNATION FOR AB-1003 VIA BRAINVECTIS

Asklepios BioPharmaceutical, Inc. (AskBio) | March 01, 2023

news image

Asklepios BioPharmaceutical, Inc. (AskBio), a subsidiary of Bayer AG, recently announced that the European Commission (EC) has granted orphan drug designation to AB-1003 (also known as LION-101) for the treatment of limb-girdle muscular dystrophy (LGMD). AB-1003 is an investigational recombinant adeno-associated virus (AAV) based gene therapy that is being developed as a one-time intravenous infusion for patients with LGMD type 2I/R9. The disease affects 4.5 people per million w...

Read More

Research, PHARMA TECH

POSITIVE RESULTS FOR AMBRX’S PROPRIETARY ANTI-PSMA ADC, ARX517, IN PROSTATE CANCER

Ambrx | February 21, 2023

news image

Ambrx Biopharma Inc., recently released positive preliminary results from its current Phase 1 trial, APEX-01 (NCT04662580), which is examining ARX517, Ambrx's patented anti-PSMA ADC, in patients with prostate cancer. Patients with advanced prostate cancer who have progressed on at least two prior FDA-approved treatments are enrolled in the Phase 1, first-in-human, open label dose escalation and dose expansion experiment known as APEX-01. In the US, APEX-01 is the only clinic...

Read More
news image

COVID-19 BRINGS DIVISIONS ON HYDROXYCHLOROQUINE, REOPENING

Fiercepharma | May 19, 2020

Welcome to the FiercePharma political roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewhere that could affect drug pricing and how drugmakers operate. As the pandemic plays out, political divisions have unfolded around hydroxychloroquine and reopening economies, for starters. At center stage last week was a House hearing over ousted Biomedical Advanced Research and Development Authority (BARDA) Director Rick Bright’s whistleblower complaint. While...

Read More
news image

Business Insights

SANOFI GLOBAL HEALTH LAUNCHES NONPROFIT IMPACT® BRAND FOR 30 MEDICINES IN LOW-INCOME COUNTRIES

Sanofi | July 05, 2022

Sanofi Global Health announces the launch of Impact®, a new brand of standard of care medicines produced by Sanofi dedicated for nonprofit distribution to at-risk populations in the world’s most impoverished countries. The Impact® brand, which includes insulin, glibenclamide and oxaliplatin amonst others, will enable the secure distribution of 30 Sanofi medicines in 40 lower-income countries. Considered essential by the World Health Organization, the medicines cover ...

Read More
news image

Research, PHARMA TECH

ASKBIO RECEIVES EC ORPHAN DRUG DESIGNATION FOR AB-1003 VIA BRAINVECTIS

Asklepios BioPharmaceutical, Inc. (AskBio) | March 01, 2023

Asklepios BioPharmaceutical, Inc. (AskBio), a subsidiary of Bayer AG, recently announced that the European Commission (EC) has granted orphan drug designation to AB-1003 (also known as LION-101) for the treatment of limb-girdle muscular dystrophy (LGMD). AB-1003 is an investigational recombinant adeno-associated virus (AAV) based gene therapy that is being developed as a one-time intravenous infusion for patients with LGMD type 2I/R9. The disease affects 4.5 people per million w...

Read More
news image

Research, PHARMA TECH

POSITIVE RESULTS FOR AMBRX’S PROPRIETARY ANTI-PSMA ADC, ARX517, IN PROSTATE CANCER

Ambrx | February 21, 2023

Ambrx Biopharma Inc., recently released positive preliminary results from its current Phase 1 trial, APEX-01 (NCT04662580), which is examining ARX517, Ambrx's patented anti-PSMA ADC, in patients with prostate cancer. Patients with advanced prostate cancer who have progressed on at least two prior FDA-approved treatments are enrolled in the Phase 1, first-in-human, open label dose escalation and dose expansion experiment known as APEX-01. In the US, APEX-01 is the only clinic...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us